Drugs / 3-acetyl-11-keto-ß-boswellic acid
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03924596 | Sep 2019 → Sep 2020 | urolithiasis | Sultan Qaboos University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3-acetyl-11-keto-ß-boswellic acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03924596 ↗ |
| Known as | AKBA-Incense | “AKBA-Incense (3-acetyl-11-keto-ß-boswellic acid)” NCT03924596 ↗ |
| Action | Inhibit | “boswellic acids, especially 11-keto-b-boswellic acid (KBA) and acetyl-11-keto-b-boswellic acid (AKBA), which were proposed as selective 5-lipoxygenase (5-LO) inhibitors” NCT03924596 ↗ |